

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

| | |
|-----------------------------------|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| Glaxo Group Limited | 03/29/2011 |
| RECEIVING PARTY DATA | |
| Name: | Dr. Reddy's Laboratories Tennessee, LLC |
| Street Address: | 200 Somerset Corporate Blvd. |
| Internal Address: | 7th Floor |
| City: | Bridgewater |
| State/Country: | NEW JERSEY |
| Postal Code: | 08807 |
| PROPERTY NUMBERS Total: 15 | |
| Property Type | Number |
| Patent Number: | 6294199 |
| Patent Number: | 6660299 |
| Patent Number: | 6051255 |
| Patent Number: | 6214359 |
| Patent Number: | 5861172 |
| Patent Number: | 5851550 |
| Patent Number: | 6110497 |
| Patent Number: | 6352720 |
| Patent Number: | 6544558 |
| Patent Number: | 6136345 |
| Patent Number: | 6358528 |
| Patent Number: | 6838094 |
| Patent Number: | 5910322 |
| Patent Number: | 6299903 |

501524417

PATENT
REEL: 026244 FRAME: 0534

CH \$600.00 6294199

Patent Number:

5670170

CORRESPONDENCE DATA

Fax Number: (908)203-6515

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 908-203-4953

Email: janisiewski@drreddys.com

Correspondent Name: Joan Anisiewski

Address Line 1: 200 Somerset Corporate Blvd.

Address Line 2: 7th Fl.

Address Line 4: Bridgewater, NEW JERSEY 08807

NAME OF SUBMITTER:

Joan Anisiewski

Total Attachments: 4

source=drl-tenn#page1.tif

source=drl-tenn#page2.tif

source=drl-tenn#page3.tif

source=drl-tenn#page4.tif

11-202

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT OF PATENTS (this "Assignment") dated as of March 29, 2011 ("Effective Date"), between and GLAXO GROUP LIMITED, a company formed under the laws of England, with a registered address at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England ("Assignor") and DR. REDDY'S LABORATORIES TENNESSEE, LLC, a Delaware limited liability company ("Assignee").

WHEREAS, Assignor and Assignee have entered into an Asset Purchase Agreement dated November 23, 2010, (the "Asset Purchase Agreement");

WHEREAS, among the assets to be transferred by Assignor to Assignee under the Asset Purchase Agreement are the patents set forth in Schedule I attached hereto (the "Patents");

WHEREAS, Assignor warrants it owns all rights title and interests in the Patents and Assignor desires to assign all rights, title, and interests in and to the Patents to Assignee; and

WHEREAS, Assignee desires to accept this Assignment.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, assign, transfer, set over, and deliver to Assignee all rights, title and interest in and to:

- (i) the Patents;
- (ii) all divisionals, continuations, continuations-in-part, reissues, extensions, re-examinations or renewal applications related to, or based on in whole or in part on, the Patents; and
- (iii) all rights of enforcement and the right to damages for past, present and future infringement, misappropriation or other conflicts relating to the Patents.

FURTHERMORE, Assignor will, at the expense of Assignee (i) execute and deliver such further instruments including, without limitation, further instruments of assignment; and (ii) take such further actions as Assignee may reasonably request in order to register this Assignment at the appropriate registries to demonstrate Assignee's title to the Patents.

This Assignment shall be binding upon the successors and assigns of Assignor and Assignee. This Assignment (including any claim or controversy arising out of or relating to this Assignment) shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed entirely within such State, without regard to the conflicts of law principles of such State. This Assignment may be executed in one or more counterparts, each of which shall be deemed and original, but all of which together shall constitute one and the same agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Assignment of Patents as of the date first written above.

**DR. REDDY'S LABORATORIES
TENNESSE, LLC**

By: _____

Name: _____

Title: _____

GLAXO GROUP LIMITED

By:  _____

Name: Edward Grimm

Title: VP - Global Head, oncology Parents

This Assignment shall be binding upon the successors and assigns of Assignor and Assignee. This Assignment (including any claim or controversy arising out of or relating to this Assignment) shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed entirely within such State, without regard to the conflicts of law principles of such State. This Assignment may be executed in one or more counterparts, each of which shall be deemed and original, but all of which together shall constitute one and the same agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Assignment of Patents as of the date first written above.

**DR. REDDY'S LABORATORIES
TENNESSE, LLC**



By: *Viswanath R. Bonthu*

Name: VISWANATHA R. BONTU

Title: SVP

GLAXO GROUP LIMITED

By: _____

Name: _____

Title: _____

SCHEDULE I

| GSK Docket No. | US Patent Number | INVENTOR | USSN | TITLE |
|----------------|------------------|-----------------|-------------------|--|
| P32555 | 6,294,199 | Conley et al. | 09/544,417 | Method of Treating a Bacterial Infection Comprising Administering Amoxicillin |
| P30921 | 6,660,299 | Conley et al. | 09/911,905 | Modified Release Pharmaceutical Formulation Comprising Amoxicillin |
| P31606 | 6,051,255 | Conley et al. | 08/727,581 | Polymer Coated Tablet Comprising Amoxicillin and Clavulanate |
| | 6,214,359 | Bax, Richard | 09/242,862 | Use of a Combination of Amoxicillin and Clavulanate In the Manufacture of a Medicament for the Treatment of Drug-Resistant <i>Streptococcus Pneumoniae</i> |
| P30048 | 5,861,172 | Martin et al. | 08/727,100 | Pharmaceutical Formulations of Compacted Granulates of β -Lactam Antibiotics |
| | 5,851,550 | Martin et al. | 729 08/792,222 | Pharmaceutical Formulations of Compacted Granulates of β -Lactam Antibiotics |
| | 6,110,497 | Martin et al. | 09/217,304 | Pharmaceutical Formulations |
| | 6,352,720 | Martin et al. | 09/645,001 | Pharmaceutical Formulations Comprised of Compacted Amoxicillin Granulates |
| | 6,544,558 | Martin et al. | 10/016,041 | Pharmaceutical Formulations Comprised of Amoxicillin in Combination with Clavulanic Acid |
| P30919 | 6,136,345 | Grimmett et al. | 08/718,550 | Tablet Containing a Coated Core |
| | 6,358,528 | Grimmett et al. | 09/640,823 | Pharmaceutical Formulation |
| | 6,838,094 | Grimmett et al. | 10/023,614 | Tablet Containing a Coated Core |
| P31707 | 5,910,322 | Rivett et al. | 08/776,909 | Delayed Release Pharmaceutical Formulation Containing Amoxicillin and Potassium Clavulanate |
| | 6,299,903 | Rivett et al. | 09/251,597 | Delayed Release Pharmaceutical Formulation Containing a of β -Lactam Antibiotic |
| B2985 | 5,670,170 | Grimmett et al. | 08/444,114 | Pharmaceutical Formulations |

PATENT